Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Home- versus office-based buprenorphine inductions for opioid-dependent patients.

Sohler NL, Li X, Kunins HV, Sacajiu G, Giovanniello A, Whitley S, Cunningham CO.

J Subst Abuse Treat. 2010 Mar;38(2):153-9. doi: 10.1016/j.jsat.2009.08.001. Epub 2009 Oct 3.

2.

A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions.

Cunningham CO, Giovanniello A, Li X, Kunins HV, Roose RJ, Sohler NL.

J Subst Abuse Treat. 2011 Jun;40(4):349-56. doi: 10.1016/j.jsat.2010.12.002. Epub 2011 Feb 18.

3.

Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.

Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O'Connor PG.

JAMA Intern Med. 2014 Dec;174(12):1947-54. doi: 10.1001/jamainternmed.2014.5302.

PMID:
25330017
4.
5.

The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with Opioid Dependence.

Accurso AJ, Rastegar DA.

J Subst Abuse Treat. 2016 Feb;61:74-9. doi: 10.1016/j.jsat.2015.09.004. Epub 2015 Oct 1.

PMID:
26639639
6.

A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic.

O'Connor PG, Oliveto AH, Shi JM, Triffleman EG, Carroll KM, Kosten TR, Rounsaville BJ, Pakes JA, Schottenfeld RS.

Am J Med. 1998 Aug;105(2):100-5.

PMID:
9727815
7.

A trial of integrated buprenorphine/naloxone and HIV clinical care.

Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA.

Clin Infect Dis. 2006 Dec 15;43 Suppl 4:S184-90.

PMID:
17109305
8.

Factors associated with complicated buprenorphine inductions.

Whitley SD, Sohler NL, Kunins HV, Giovanniello A, Li X, Sacajiu G, Cunningham CO.

J Subst Abuse Treat. 2010 Jul;39(1):51-7. doi: 10.1016/j.jsat.2010.04.001.

9.

Buprenorphine implants and opioid dependence.

Rastegar DA.

JAMA. 2011 Jan 19;305(3):253; author reply 254-5. doi: 10.1001/jama.2010.1988. No abstract available.

PMID:
21245178
10.

The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence.

Sullivan LE, Moore BA, O'Connor PG, Barry DT, Chawarski MC, Schottenfeld RS, Fiellin DA.

Am J Addict. 2010 Jan-Feb;19(1):53-8. doi: 10.1111/j.1521-0391.2009.00003.x.

11.

The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?

Sullivan LE, Chawarski M, O'Connor PG, Schottenfeld RS, Fiellin DA.

Drug Alcohol Depend. 2005 Jul;79(1):113-6.

PMID:
15943950
12.

Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling.

Kornør H, Waal H, Ali RL.

Drug Alcohol Rev. 2006 Mar;25(2):123-30. Erratum in: Drug Alcohol Rev. 2009 Mar;28(2):217. Dosage error in article text.

PMID:
16627301
14.

Association between hepatitis C virus and opioid use while in buprenorphine treatment: preliminary findings.

Murphy SM, Dweik D, McPherson S, Roll JM.

Am J Drug Alcohol Abuse. 2015 Jan;41(1):88-92. doi: 10.3109/00952990.2014.983274.

15.

Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.

Rosenthal RN, Lofwall MR, Kim S, Chen M, Beebe KL, Vocci FJ; PRO-814 Study Group.

JAMA. 2016 Jul 19;316(3):282-90. doi: 10.1001/jama.2016.9382.

PMID:
27434441
16.

A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence.

Pérez de los Cobos J, Martin S, Etcheberrigaray A, Trujols J, Batlle F, Tejero A, Queraltó JM, Casas M.

Drug Alcohol Depend. 2000 Jun 1;59(3):223-33.

PMID:
10812283
17.

Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.

Clay E, Khemiri A, Zah V, Aballéa S, Ruby J, Asche CV.

J Med Econ. 2014 Sep;17(9):626-36. doi: 10.3111/13696998.2014.925463. Epub 2014 Jun 6.

PMID:
24841329
18.

Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians.

Arfken CL, Johanson CE, di Menza S, Schuster CR.

J Subst Abuse Treat. 2010 Sep;39(2):96-104. doi: 10.1016/j.jsat.2010.05.004. Epub 2010 Jul 3.

PMID:
20598829
19.

Implementation of a collaborative care management program with buprenorphine in primary care: a comparison between opioid-dependent patients and patients with chronic pain using opioids nonmedically.

Suzuki J, Matthews ML, Brick D, Nguyen MT, Wasan AD, Jamison RN, Ellner AL, Tishler LW, Weiss RD.

J Opioid Manag. 2014 May-Jun;10(3):159-68. doi: 10.5055/jom.2014.0204. Erratum in: J Opioid Manag. 2014 Sep-Oct;10(5):302. Wasan, Ajay D [added].

20.

Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.

Gunderson EW, Hjelmström P, Sumner M; 006 Study Investigators.

Clin Ther. 2015 Oct 1;37(10):2244-55. doi: 10.1016/j.clinthera.2015.08.025. Epub 2015 Sep 26.

Supplemental Content

Support Center